Food Testing MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Testing TypeBy Food TestedBy Service Provider
Full title & scope — all 5 axes with their segments
Food Testing Market Size, Share & Industry Analysis, By Type (Immunoassay Systems, Chromatography Systems, Mass Spectrometry Systems), By Application (Food Processing Plants, Food Safety Institutions, Other), By Testing Type (Microbiological Testing, Allergen Testing, Pesticide Testing, Tests on GMOs, Tests for Toxins, Testing for nutrition, Other Types of Testing), By Food Tested (Processed Foods, Meat, Poultry and Seafood Products, Dairy Products, Fruits and Vegetables, Beverages, Cereals and Grains, Other Food Products), By Service Provider (Third-Party/Outsourced Testing, In-house Testing), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.

- 01By TypeImmunoassay Systems · Chromatography Systems · Mass Spectrometry Systems
- 02By ApplicationFood Processing Plants · Food Safety Institutions · Other
- 03By Testing TypeMicrobiological Testing · Allergen Testing · Pesticide Testing
- 04By Food TestedProcessed Foods · Meat, Poultry and Seafood Products · Dairy Products
- 05By Service ProviderThird-Party/Outsourced Testing · In-house Testing
- 06By Region
Market Analysis & Outlook
Food testing covers the analytical services and instrumentation used to verify that raw ingredients, processed foods, and beverages are safe for consumption and meet regulatory and label claims before they reach a retail shelf or export market. It spans microbiological, chemical, and physical testing performed in commercial laboratories, in-house quality-control facilities, and government or independent certification bodies. Buyers range from food and beverage processors and packers to retailers, exporters, and regulatory agencies that require documented proof of compliance before a shipment or product line can be sold.
Growth of 8.1% a year carries the global food testing market from USD 25.6 billion in 2025 to USD 51.66 billion in 2034. The full series behind that rate covers USD 16.9 billion in 2020, USD 23.7 billion in 2024, USD 27.7 billion in 2026 and USD 37.84 billion in 2030, with 2025 as the base year.
On the type axis, growth rates run from 6.76% for Immunoassay Systems up to 10.67% for Mass Spectrometry Systems. Immunoassay Systems carries the volume: USD 10.88 billion and 42.5% of revenue in 2025, USD 19.631 billion and 38% in 2034. Share moves toward Mass Spectrometry Systems and away from Immunoassay Systems and Chromatography Systems, though no line shrinks in revenue terms.
By application, Food Processing Plants accounts for 58% of 2025 revenue at USD 14.848 billion, reaching USD 29.446 billion and 57% by 2034. Food Safety Institutions grows faster at 9.4% against 7.86%, moving from 30% of revenue to 33% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.
The regional order runs from North America at 31.57% of 2025 revenue down to Middle East and Africa at 6%. North America is worth USD 8.082 billion in 2025 and USD 14.981 billion in 2034; Asia Pacific, second at 28.5%, moves from USD 7.296 billion to USD 17.048 billion. Because Asia Pacific take share, the revenue added by 2034 concentrates rather than spreading across all five regions.
The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, three type lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 25.6 billion in 2025 to USD 51.66 billion in 2034, a compound annual rate of 8.1%, having reached USD 23.7 billion in 2024 from USD 16.9 billion in 2020.
- Immunoassay Systems is the largest type line at USD 10.88 billion in 2025, a 42.5% share, reaching USD 19.631 billion and 38% of revenue by 2034.
- Fastest growth on the type axis belongs to Mass Spectrometry Systems: 10.67% a year, USD 6.198 billion to USD 15.498 billion, and a share moving from 24.21% to 30%.
- The bull case puts 2034 revenue at USD 56.83 billion and the bear case at USD 46.49 billion, either side of the USD 51.66 billion base case, each with its own stated assumption in the full report.
- The largest region is North America, generating USD 8.082 billion in 2025 (31.57% of the global total) and USD 14.981 billion by 2034, ahead of Asia Pacific at 28.5%.
- 80% of North America's base-year revenue comes from the United States alone: USD 6.466 billion in 2025, rising to USD 11.985 billion by 2034, which is why it is that region's worked example.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By By Type
Base year 2025Immunoassay Systems leads with 42.5% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Read across the forecast period, the global food testing market shows movement in three places: type composition, regional weight, and the 8.1% rate applied to the whole.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.
Mass Spectrometry Systems outpaces Immunoassay Systems. Mass Spectrometry Systems grows at 10.67% across 2026-2034 against 6.76% for Immunoassay Systems, the widest spread on the type axis. By 2034 the two sit at 30% and 38% of revenue, against 24.21% and 42.5% in 2025. Revenue rises on both sides; USD 6.198 billion to USD 15.498 billion and USD 10.88 billion to USD 19.631 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Asia Pacific gain regional share. Asia Pacific moves from 28.5% of revenue in 2025 to 33% in 2034, worth USD 7.296 billion rising to USD 17.048 billion. Share moves off the others in turn: North America at 31.57% moving to 29%, Europe at 25.93% moving to 24%, Latin America at 8% moving to 8%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
The series never breaks trajectory. The market moves through USD 16.9 billion in 2020, USD 23.7 billion in 2024, USD 25.6 billion in 2025, USD 27.7 billion in 2026, USD 37.84 billion in 2030 and USD 51.66 billion in 2034. Against 8.66% through the historical period, the 8.1% forecast rate is a continuation; no year in the series interrupts it. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.
Market Growth Factors
Growth is concentrated in Mass Spectrometry Systems
Market Drivers
3- 01Growth is concentrated in Mass Spectrometry Systems
10.67% growth in Mass Spectrometry Systems, against 8.1% for the market as a whole, moves it from USD 6.198 billion and 24.21% of revenue in 2025 to USD 15.498 billion and 30% in 2034. Set against 6.76% at the other end of the axis, this is the line that decides whether the market's 8.1% holds. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Growth lands where the revenue already is
North America is the largest region at USD 8.082 billion in 2025, 31.57% of global revenue, and reaches USD 14.981 billion by 2034 while holding 29%. Asia Pacific is next at 28.5% of revenue, USD 7.296 billion in 2025 and USD 17.048 billion in 2034. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03The base has grown every year since 2020
USD 16.9 billion in 2020, USD 23.7 billion in 2024 and USD 25.6 billion in 2025: 8.66% compound growth before the forecast period even begins. The forecast period then runs at 8.1%, ending 2034 at USD 51.66 billion. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory rather than a projected turnaround, and it is why the 8.1% rate is applied across the whole period rather than ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Tightening food safety regulation and mandatory testing mandates | High | +9 | High | High | High |
| 2 | Rising global food trade and export compliance testing | High | +7 | High | High | Medium |
| 3 | Growing adoption of rapid and molecular testing technologies | Medium-High | +5.5 | Medium | High | High |
| 4 | Increasing food recalls raising retailer-driven testing requirements | Medium-High | +4 | High | Medium | Medium |
| 5 | Expansion of processed and packaged food consumption in emerging markets | Medium | +2.5 | Medium | Medium | Medium |
| 6 | Others | Low | +1.06 | Low | Low | Low |
| Total | +29.06 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High cost of advanced instrumentation limiting adoption among small and mid-size processors | Medium | −1.5 | Medium | Medium | Low |
| 2 | Shortage of skilled laboratory personnel in emerging markets | Medium | −1 | Medium | Medium | Medium |
| 3 | Lengthy turnaround times for confirmatory testing methods slowing throughput gains | Low | −0.5 | Low | Low | Low |
| Total | −3 | |||||
Drivers contribute 29.06 Billion and restraints remove 3 Billion, a net 26.06 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 8.1% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 46.49 billion rather than USD 51.66 billion by 2034
Market Restraints
2- 01Downside case: USD 46.49 billion rather than USD 51.66 billion by 2034
The study's downside path assumes bear case assumes delayed enforcement of new testing mandates in major markets and slower instrumentation upgrade cycles as processors defer capital spending, and ends 2034 at USD 46.49 billion against the USD 51.66 billion base case, the same USD 25.6 billion base year, a slower forecast period.
- 02Immunoassay Systems grows below the market rate
Immunoassay Systems carries 42.5% of 2025 revenue at USD 10.88 billion but compounds at 6.76% against 8.1% for the market, taking its share to 38% by 2034 even as revenue rises to USD 19.631 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
A bull case of USD 56.83 billion by 2034, against USD 51.66 billion in the base case, turns on a single stated assumption: bull case assumes faster-than-expected regulatory tightening in emerging export markets and quicker conversion of routine screening volume from immunoassay to mass spectrometry platforms. The USD 25.6 billion 2025 base is common to both.
- 02The opening is on the type axis, not the regional one
Mass Spectrometry Systems grows at 10.67% against 8.1% for the market, adding revenue from USD 6.198 billion in 2025 to USD 15.498 billion in 2034 and taking its share from 24.21% to 30%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Immunoassay Systems.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
With 42.5% of 2025 revenue and 38% of 2034 revenue (USD 10.88 billion rising to USD 19.631 billion) Immunoassay Systems is where the market's exposure sits. No other single change on the type axis moves the total as much as a change in demand for that one line.
- 02North America is largely the United States
The United States generates USD 6.466 billion of North America's USD 8.082 billion in 2025, 80% of the region, reaching USD 11.985 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe global food testing market is cut five ways: by type, application, testing type, food tested and service provider. Revenue does not add across them: each is a different cut of the same total.
Three type lines are reported. One of them takes share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Type · 3 segments
Immunoassay Systems Held the Dominant Share of the Type Segment in 2025
- Largest Immunoassay Systems · 42.5%
- Fastest Mass Spectrometry Systems · 10.7%
- Moves most Mass Spectrometry Systems · +5.8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Immunoassay Systems | $10.88B | 42.5% | $19.63B | 38%-4.5 | 6.8% |
| Chromatography Systems | $8.52B | 33.3% | $16.53B | 32%-1.3 | 7.6% |
| Mass Spectrometry Systems | $6.20B | 24.2% | $15.50B | 30%+5.8 | 10.7% |
Immunoassay platforms lead because they offer the fastest, lowest-cost route to routine pathogen and contaminant screening, making them the default choice for high-volume production-line testing. Mass spectrometry systems are gaining fastest because confirmatory and multi-residue pesticide and toxin testing increasingly requires trace-level accuracy that immunoassay and chromatography alone cannot reliably deliver. By 2034 Immunoassay Systems is still ahead, making this a shift in weight rather than a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Application · 3 segments
Scale in Food Processing Plants and Growth in Food Safety Institutions Define the Application Axis
- Largest Food Processing Plants · 58%
- Fastest Food Safety Institutions · 9.4%
- Moves most Food Safety Institutions · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Food Processing Plants | $14.85B | 58% | $29.45B | 57%-1 | 7.9% |
| Food Safety Institutions | $7.68B | 30% | $17.05B | 33%+3 | 9.4% |
| Other | $3.07B | 12% | $5.17B | 10%-2 | 5.7% |
Food processing plants lead because testing is embedded directly into their production and release workflows, making it a recurring operating cost rather than a discretionary purchase. Food safety institutions are growing fastest as governments and independent bodies expand mandatory inspection and verification programs, shifting a larger share of testing away from voluntary in-house checks. The order does not change: Food Processing Plants is still largest in 2034, and what moves is how much it holds.
By Testing Type · 7 segments
By Testing Type
- Largest Microbiological Testing · 35%
- Fastest Allergen Testing · 10.8%
- Moves most Allergen Testing · +3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Microbiological Testing | $8.96B | 35% | $17.05B | 33%-2 | 7.3% |
| Allergen Testing | $3.58B | 14% | $8.78B | 17%+3 | 10.8% |
| Pesticide Testing | $4.61B | 18% | $8.78B | 17%-1 | 7.3% |
| Tests on GMOs | $2.05B | 8% | $4.65B | 9%+1 | 9.7% |
| Tests for Toxins | $3.07B | 12% | $5.68B | 11%-1 | 6.9% |
| Testing for nutrition | $2.05B | 8% | $4.13B | 8% | 8.1% |
| Other Types of Testing | $1.28B | 5% | $2.58B | 5% | 8.1% |
2025 to 2034 revenue and share by line: Microbiological Testing USD 8.96 billion to USD 17.048 billion (35% to 33%), Pesticide Testing USD 4.608 billion to USD 8.782 billion (18% to 17%), Allergen Testing USD 3.584 billion to USD 8.782 billion (14% to 17%), Tests for Toxins USD 3.072 billion to USD 5.683 billion (12% to 11%), Tests on GMOs USD 2.048 billion to USD 4.649 billion (8% to 9%), Testing for nutrition USD 2.048 billion to USD 4.133 billion (8% to 8%), Other Types of Testing USD 1.28 billion to USD 2.583 billion (5% to 5%). Scale in Microbiological Testing and Growth in Allergen Testing Define the Testing type Axis Microbiological testing leads because pathogen contamination remains the most immediate safety and recall risk across nearly every food category, making it the baseline test almost no processor skips. Allergen testing is growing fastest as mandatory allergen labeling rules broaden and diagnosed food allergy prevalence rises, pushing processors to verify claims they previously stated without testing. The order does not change: Microbiological Testing is still largest in 2034, and what moves is how much it holds.
By Food Tested · 7 segments
By Food Tested
- Largest Processed Foods · 26%
- Fastest Fruits and Vegetables · 10.8%
- Moves most Fruits and Vegetables · +3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Processed Foods | $6.66B | 26% | $12.91B | 25%-1 | 7.6% |
| Meat, Poultry and Seafood Products | $5.63B | 22% | $10.85B | 21%-1 | 7.5% |
| Dairy Products | $4.10B | 16% | $7.75B | 15%-1 | 7.2% |
| Fruits and Vegetables | $3.58B | 14% | $8.78B | 17%+3 | 10.8% |
| Beverages | $2.56B | 10% | $5.17B | 10% | 8.1% |
| Cereals and Grains | $2.05B | 8% | $4.13B | 8% | 8.1% |
| Other Food Products | $1.02B | 4% | $2.07B | 4% | 8.1% |
2025 to 2034 revenue and share by line: Processed Foods USD 6.656 billion to USD 12.915 billion (26% to 25%), Meat, Poultry and Seafood Products USD 5.632 billion to USD 10.849 billion (22% to 21%), Dairy Products USD 4.096 billion to USD 7.749 billion (16% to 15%), Fruits and Vegetables USD 3.584 billion to USD 8.782 billion (14% to 17%), Beverages USD 2.56 billion to USD 5.166 billion (10% to 10%), Cereals and Grains USD 2.048 billion to USD 4.133 billion (8% to 8%), Other Food Products USD 1.024 billion to USD 2.066 billion (4% to 4%). Fruits and Vegetables Outpaces the Axis While Processed Foods Holds the Largest Share Processed foods lead because the category spans the widest range of ingredients, additives and contamination pathways, requiring more test types per product than any single raw commodity. Fruits and vegetables are growing fastest as fresh-produce recall incidents rise and export markets tighten residue and phytosanitary compliance requirements on commodities that were historically tested far less often. Processed Foods remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Service Provider · 2 segments
Third-Party/Outsourced Testing Both Leads the Service provider Axis and Grows Fastest on It
- Largest Third-Party/Outsourced Testing · 55%
- Fastest Third-Party/Outsourced Testing · 9.3%
- Moves most Third-Party/Outsourced Testing · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Third-Party/Outsourced Testing | $14.08B | 55% | $31B | 60%+5 | 9.3% |
| In-house Testing | $11.52B | 45% | $20.66B | 40%-5 | 6.5% |
Third-party testing leads and is also growing fastest because independent verification carries more credibility with regulators, retailers and export partners than results generated in-house. Outsourcing also lets processors access advanced confirmatory instrumentation without owning it, which matters most for mid-size producers that cannot justify a full in-house laboratory. The order does not change: Third-Party/Outsourced Testing is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025
Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 2.6 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 1 of 5
- 2025 share 31.6%
- By 2034 29%
- Revenue $8.08B → $14.98B
USD 8.082 billion of 2025 revenue is generated in North America, 31.57% of the global food testing market rising to USD 14.981 billion in 2034. Among the five regions it ranks first by revenue in both years.
Its share moves to 29% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the type split tracks the global one; 42.5% of 2025 revenue in Immunoassay Systems, fastest growth of 10.67% in Mass Spectrometry Systems. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 80% of it, growing 1.9×.
- In region 1 of 2
- Of region 80%
- Of global 25.3%
- Revenue $6.47B → $11.98B
The United States is the largest market within North America, generating USD 6.466 billion in 2025 and projected to reach USD 11.985 billion by 2034. At 80% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 8.082 billion and USD 14.981 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Demand in the United States follows the type mix reported at global level: Immunoassay Systems is the largest line at 42.5% of 2025 revenue, moving to 38% by 2034, while Mass Spectrometry Systems grows fastest at 10.67% and takes its share from 24.21% to 30%. Because the country carries 80% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The United States carries its own type breakdown in the full report.
In the United States, food testing laboratories and the suppliers who rely on them operate under the framework set out by the Food and Drug Administration together with the Department of Agriculture's Food Safety and Inspection Service, depending on the commodity class involved. The Food Safety Modernization Act shapes preventive-control expectations that testing must support, while the Federal Food, Drug, and Cosmetic Act underpins labeling and adulteration standards. Laboratories submitting data in support of regulatory decisions are generally expected to hold accreditation to the ISO/IEC standard governing testing and calibration competence, often administered through recognized national accreditation bodies. Suppliers must ensure methods are validated, results are traceable, and reporting aligns with the applicable agency's guidance documents before products move through interstate commerce.
SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality are the suppliers covered in the United States. Two different problems sit on the same axis: holding Immunoassay Systems at 42.5% of 2025 revenue, and taking Mass Spectrometry Systems while it grows at 10.67%. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 1.9×.
- In region 2 of 2
- Of region 20%
- Of global 6.3%
- Revenue $1.62B → $3B
Canada is sized at USD 1.616 billion in 2025, rising to USD 2.996 billion by 2034; 6.31% of global revenue and 20% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 3rd-largest region covered — 1.9 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 3 of 5
- 2025 share 25.9%
- By 2034 24%
- Revenue $6.64B → $12.40B
Europe holds 25.93% of the global food testing market in 2025, worth USD 6.638 billion with USD 12.398 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 24% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
The type mix reported at global level applies here, with Immunoassay Systems the largest line at 42.5% of 2025 revenue and Mass Spectrometry Systems the fastest-growing at 10.67%. Per-axis and per-country detail for Europe sits in the full report.
Germany
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 32%
- Of global 8.3%
- Revenue $2.12B → $3.84B
USD 2.124 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 3.843 billion by 2034. It accounts for 32% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 6.638 billion to USD 12.398 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Immunoassay Systems at 42.5% of 2025 revenue, easing to 38% by 2034, and the fastest is Mass Spectrometry Systems at 10.67%, from 24.21% to 30%. Its 32% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.
In Germany, food testing activity sits within the wider European Union food law framework, anchored by the EU General Food Law and enforced domestically through the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit alongside state-level food monitoring authorities. Testing providers are expected to demonstrate impartiality and technical competence in line with the EN ISO/IEC standard for laboratory accreditation, typically overseen by the national accreditation body, DAkkS. Suppliers of testing services must apply validated methods aligned with Codex Alimentarius principles where relevant, maintain traceable documentation, and support labeling claims that satisfy both EU-wide requirements and any additional national provisions on food information to consumers. Non-conformities identified during official controls can trigger corrective action requirements before affected products may remain on the market.
The suppliers tracked in this study (SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality) compete in Germany across the type lines above. Immunoassay Systems, at 42.5% of 2025 revenue, is where the volume sits, and Mass Spectrometry Systems, growing at 10.67%, is where position changes hands over the forecast period.
United Kingdom
2nd-largest in Europe, growing 1.9×.
- In region 2 of 3
- Of region 27%
- Of global 7%
- Revenue $1.79B → $3.35B
7% of global revenue is generated in the United Kingdom; USD 1.792 billion in 2025, reaching USD 3.347 billion in 2034, and 27% of Europe.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 22%
- Of global 5.7%
- Revenue $1.46B → $2.60B
5.7% of global revenue is generated in France; USD 1.46 billion in 2025, reaching USD 2.604 billion in 2034, and 22% of Europe.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 4.5 points of share by 2034, while revenue still grows 2.3×.
- Rank 2 of 5
- 2025 share 28.5%
- By 2034 33%
- Revenue $7.30B → $17.05B
In Asia Pacific, 28.5% of global revenue puts 2025 at USD 7.296 billion on the way to USD 17.048 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.
33% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 8.1%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the type split tracks the global one; 42.5% of 2025 revenue in Immunoassay Systems, fastest growth of 10.67% in Mass Spectrometry Systems. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.5×.
- In region 1 of 3
- Of region 38%
- Of global 10.8%
- Revenue $2.77B → $6.82B
The largest single market in Asia Pacific is China, at USD 2.772 billion in 2025 and USD 6.819 billion in 2034. Its 38% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Against regional totals of USD 7.296 billion in 2025 and USD 17.048 billion in 2034, it is the country the full report breaks out in detail.
The type pattern in China is the global one: 42.5% of 2025 revenue in Immunoassay Systems, 38% by 2034, against 10.67% growth in Mass Spectrometry Systems taking it from 24.21% to 30%. Its 38% weight in Asia Pacific means those movements carry straight into the regional totals. Revenue by type for China is reported separately in the full report.
In China, food testing falls under the oversight of the State Administration for Market Regulation, working alongside the National Health Commission on the development and enforcement of national food safety standards, commonly referenced as GB standards. Laboratories offering testing services are expected to obtain certification through the China Metrology Accreditation scheme and, where relevant, accreditation from the China National Accreditation Service for Conformity Assessment, demonstrating competence and impartiality. Suppliers must ensure that products are classified correctly under the applicable national standard, that testing methods match those prescribed or recognized by regulators, and that labeling and safety claims are consistent with verified results. Imported goods face additional customs and inspection requirements before distribution is permitted domestically.
SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality are the suppliers covered in China. Volume sits in Immunoassay Systems at 42.5% of 2025 revenue; movement sits in Mass Spectrometry Systems at 10.67% growth.
India
2nd-largest in Asia Pacific, growing 2.7×.
- In region 2 of 3
- Of region 22%
- Of global 6.3%
- Revenue $1.60B → $4.26B
6.27% of global revenue is generated in India; USD 1.605 billion in 2025, reaching USD 4.262 billion in 2034, and 22% of Asia Pacific.
Japan
3rd-largest in Asia Pacific, growing 2.1×.
- In region 3 of 3
- Of region 18%
- Of global 5.1%
- Revenue $1.31B → $2.73B
Within Asia Pacific, Japan accounts for 18% of regional revenue and 5.13% of the global total, worth USD 1.313 billion in 2025 and USD 2.728 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 4 of 5
- 2025 share 8%
- By 2034 8%
- Revenue $2.05B → $4.13B
USD 2.048 billion of 2025 revenue is generated in Latin America, 8% of the global food testing market rising to USD 4.133 billion in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
Share settles at 8% in 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
The type mix reported at global level applies here, with Immunoassay Systems the largest line at 42.5% of 2025 revenue and Mass Spectrometry Systems the fastest-growing at 10.67%. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 48%
- Of global 3.8%
- Revenue $0.98B → $1.98B
48% of Latin America's base-year revenue comes from Brazil; USD 0.983 billion, rising to USD 1.984 billion by 2034. Its 48% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. The region itself runs USD 2.048 billion to USD 4.133 billion over the same period, and this is the market carrying the country-level detail in the full report.
The type pattern in Brazil is the global one: 42.5% of 2025 revenue in Immunoassay Systems, 38% by 2034, against 10.67% growth in Mass Spectrometry Systems taking it from 24.21% to 30%. With 48% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by type separately.
In Brazil, food testing is governed principally by the Agência Nacional de Vigilância Sanitária, which sets health and safety requirements for food products, alongside the Ministério da Agricultura, Pecuária e Abastecimento for agricultural and animal-origin commodities. Laboratory competence is assessed against accreditation criteria maintained by the Instituto Nacional de Metrologia, Qualidade e Tecnologia, drawing on internationally recognized standards for testing and calibration bodies. Suppliers are required to classify products correctly, validate testing methods against the relevant regulatory framework, and ensure labeling reflects verified composition and safety data. Where products cross into export markets, conformity with destination-country requirements and Codex Alimentarius guidance is also expected, adding a further layer of documentation for testing providers to satisfy.
In Brazil the field is SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality. Two different problems sit on the same axis: holding Immunoassay Systems at 42.5% of 2025 revenue, and taking Mass Spectrometry Systems while it grows at 10.67%.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 32%
- Of global 2.6%
- Revenue $0.66B → $1.32B
2.56% of global revenue is generated in Mexico; USD 0.655 billion in 2025, reaching USD 1.323 billion in 2034, and 32% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $1.54B → $3.10B
In Middle East and Africa, 6% of global revenue puts 2025 at USD 1.536 billion rising to USD 3.1 billion in 2034. Among the five regions it ranks fifth by revenue in both years.
By 2034 the share stands at 6%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
The type mix reported at global level applies here, with Immunoassay Systems the largest line at 42.5% of 2025 revenue and Mass Spectrometry Systems the fastest-growing at 10.67%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.0×.
- In region 1 of 2
- Of region 35%
- Of global 2.1%
- Revenue $0.54B → $1.08B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.538 billion in 2025 and USD 1.085 billion in 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 1.536 billion to USD 3.1 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Immunoassay Systems at 42.5% of 2025 revenue, easing to 38% by 2034, and the fastest is Mass Spectrometry Systems at 10.67%, from 24.21% to 30%. With 35% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Saudi Arabia by type separately.
In Saudi Arabia, the Saudi Food and Drug Authority sets the principal framework governing food testing, working in conjunction with the Saudi Standards, Metrology and Quality Organization and, at the regional level, standards issued through the Gulf Standardization Organization. Testing laboratories are expected to hold accreditation demonstrating competence and impartiality, generally aligned with internationally recognized standards for testing and calibration bodies. Suppliers must ensure that products are classified appropriately, that halal compliance is verified where applicable, and that labeling and safety claims match validated test results before goods reach the market. Imported food products face additional conformity assessment and customs verification steps administered through the kingdom's broader product safety program.
SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality are the suppliers covered in Saudi Arabia. The commercially relevant division is 42.5% of 2025 revenue in Immunoassay Systems, where the volume is, against 10.67% growth in Mass Spectrometry Systems, where share moves.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 30%
- Of global 1.8%
- Revenue $0.46B → $0.93B
Within Middle East and Africa, South Africa accounts for 30% of regional revenue and 1.8% of the global total, worth USD 0.461 billion in 2025 and USD 0.93 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Testing Type, Food Tested, Service Provider, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Type Axis Decides Competitive Standing
The study covers twelve suppliers: SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs and AsureQuality.
The competitive line that matters is the type one, not the geographic one. 42.5% of 2025 revenue, worth USD 10.88 billion, is in Immunoassay Systems, still 38% of the total in 2034; that is the position least likely to change hands. The line that changes hands is Mass Spectrometry Systems at 10.67%, well ahead of Immunoassay Systems at 6.76%. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 25.6 billion.
Scale in accredited laboratory networks and breadth of regulatory approvals across export destinations separate the leading players from regional specialists: global testing groups can serve a multinational processor from a single contract and turn around confirmatory results across jurisdictions without subcontracting. Smaller and regional labs compete instead on turnaround speed for routine screens, proximity to processing clusters, and lower pricing for high-volume, low-complexity tests such as microbiological panels. Instrument breadth, particularly access to mass spectrometry for multi-residue confirmatory work, remains concentrated among the larger groups, while private-label and co-branded testing programs for retailers are becoming a meaningful differentiator for mid-size providers seeking direct retailer relationships.
Presence matters unevenly by region. With 31.57% of 2025 revenue in North America and 28.5% in Asia Pacific, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Food Testing Market Companies Profiled
12 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- SGS SA(Switzerland)
- Intertek Group plc(United Kingdom)
- Eurofins Scientific(Luxembourg)
- Bureau Veritas S.A(France)
- Silliker(United States)
- ALS Ltd(Australia)
- Mérieux NutriSciences(United States)
- TÜV SÜD(Germany)
- Microbac Laboratories(United States)
- Neogen Corporation(United States)
- Romer Labs(Austria)
- AsureQuality(New Zealand)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, Testing Type, Food Tested, Service Provider), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 12 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Food Testing Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Food Testing Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Food Testing Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Food Testing Market Overview, By Testing Type, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Food Testing Market Overview, By Food Tested, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Food Testing Market Overview, By Service Provider, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Food Testing Market Size — Segment Comparison
Chapter 22.Global Food Testing Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Food Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Food Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Food Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Food Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Food Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
3- 01Immunoassay Systems
- 02Chromatography Systems
- 03Mass Spectrometry Systems
By Application
3- 01Food Processing Plants
- 02Food Safety Institutions
- 03Other
By Testing Type
7- 01Microbiological Testing
- 02Allergen Testing
- 03Pesticide Testing
- 04Tests on GMOs
- 05Tests for Toxins
- 06Testing for nutrition
- 07Other Types of Testing
By Food Tested
7- 01Processed Foods
- 02Meat, Poultry and Seafood Products
- 03Dairy Products
- 04Fruits and Vegetables
- 05Beverages
- 06Cereals and Grains
- 07Other Food Products
By Service Provider
2- 01Third-Party/Outsourced Testing
- 02In-house Testing
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews were directed at laboratory operations managers, procurement and quality-assurance leads at food processors, and regulatory affairs staff at national food safety agencies, the roles that set testing frequency, choose accredited providers, and interpret compliance thresholds. Channel conversations covered both in-house laboratory operators and third-party testing groups to capture how the make-or-outsource decision is actually made. Sampling weighted North America and Europe, where accreditation and disclosure practices are most mature and where the largest testing groups are headquartered, with additional coverage in China and India to capture laboratory capacity build-out and rising export compliance testing.
Desk research drew on ISO/IEC 17025 accreditation registers to establish laboratory counts by country, national food safety agency inspection and recall databases (including FDA recall notices and EU RASFF alerts) to track testing-driven enforcement activity, and HS code import and export trade data for food categories subject to mandatory residue and contaminant testing at customs. Codex Alimentarius standards and regional maximum-residue-limit registers were used to identify which testing types are mandated in which markets. Publicly filed segment revenue from the major listed testing and certification groups was used as the top-down check described above.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the pace at which mandatory testing requirements are expanding into categories and markets that do not yet test at developed-market intensity, and from the rate at which laboratories convert routine screening volume from immunoassay to mass spectrometry platforms as instrument costs fall. Pricing is held roughly flat in real terms, since testing prices have historically moved with instrument amortisation and reagent cost rather than demand. The forecast assumes no major relaxation of food safety enforcement in the two largest testing markets and normalises for the temporary volume spike recall events cause in the year they occur rather than projecting that spike forward.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Historical output was back-tested against recorded segment growth reported by the largest listed testing groups over 2020-2024 to confirm the bottom-up build tracked disclosed trends rather than diverging from them. Segment share shifts, particularly the move toward mass spectrometry and toward third-party outsourced testing, were reviewed against the primary interviews described above rather than assumed to continue past trends unchecked. Sensitivities were tested on the two assumptions the forecast depends on most: the pace of mandatory-testing expansion in emerging markets and the rate of platform conversion from immunoassay to mass spectrometry, since both have the largest effect on which sub-segment carries the incremental revenue.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is highest for the instrumentation and application splits, which can be anchored to accreditation counts and the disclosed segment revenue of the largest listed testing groups. It is lower for the food-tested and service-provider splits in emerging markets, where laboratory capacity data is thinner and a meaningful share of in-house testing is never separately reported. The clearest risk to the forecast is a change in enforcement intensity, either a relaxation that slows mandated testing growth or a major contamination event that pulls testing volume forward faster than modelled here.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Food Testing Market projected to reach?
USD 51.66 Billion by 2034, CAGR 8.1%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 31.57% of global revenue through 2034.
05Which segment leads the market?
Immunoassay Systems is the largest line by Type, at 42.5% of revenue in 2025.
06Who are the key companies profiled?
SGS SA, Intertek Group plc, Eurofins Scientific, Bureau Veritas S.A, Silliker, ALS Ltd, Mérieux NutriSciences, TÜV SÜD, Microbac Laboratories, Neogen Corporation, Romer Labs, AsureQuality. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.